What Is Multiple Myeloma?

Multiple myeloma occurs when plasma cells, a type of white blood cell found in bone marrow, begin to grow out of control. These plasma cells are an important part of the immune system and normally produce antibodies that help fight infections. In myeloma, cancerous plasma cells produce abnormal proteins instead of helpful antibodies.

This blood cancer typically develops in individuals over 65 years of age, though younger people can also be affected. Myeloma is considered the second most common blood cancer, yet many people remain unfamiliar with its symptoms and progression. The disease can exist in several forms, including smoldering myeloma (a precancerous condition) and active multiple myeloma that requires immediate treatment.

Recognizing Myeloma Symptoms

Detecting myeloma early can be challenging as symptoms often don't appear until the disease has advanced. The most common symptoms can be remembered using the CRAB criteria: Calcium elevation, Renal (kidney) problems, Anemia, and Bone damage or pain.

Patients often experience persistent bone pain, particularly in the back, ribs, or hips. Frequent infections, unusual bruising or bleeding, and persistent fatigue are also warning signs. Many patients report feeling unusually tired despite adequate rest, which is typically related to anemia caused by the cancer's impact on bone marrow function. Other symptoms might include unexplained weight loss, mental confusion, and increased thirst due to high calcium levels in the blood.

Diagnosis and Staging of Myeloma

Diagnosing myeloma involves several tests, including blood and urine tests to detect abnormal proteins (M proteins), bone marrow biopsies to examine plasma cells, and imaging studies to identify bone damage. A complete blood count may reveal anemia, while specialized tests like serum protein electrophoresis can identify paraproteins produced by myeloma cells.

Once diagnosed, myeloma is staged to determine its progression. The International Staging System (ISS) uses blood test results to classify myeloma into three stages. Additionally, doctors use genetic testing of myeloma cells to identify high-risk features that might affect treatment decisions. Modern diagnostic approaches now include more sophisticated tests like fluorescence in situ hybridization (FISH) to detect specific genetic abnormalities in myeloma cells. These comprehensive assessments help oncologists develop personalized treatment plans.

Treatment Options Comparison

Treatment for multiple myeloma has evolved significantly in recent years, with several approaches available depending on the patient's age, overall health, and disease stage. The main categories include chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation.

The Multiple Myeloma Research Foundation provides resources about various treatment options. For newly diagnosed patients, initial therapy often includes combinations of drugs from different classes, such as proteasome inhibitors, immunomodulatory drugs, and corticosteroids. The Leukemia & Lymphoma Society offers support for patients navigating treatment decisions.

For eligible patients, high-dose chemotherapy followed by autologous stem cell transplant remains a standard approach that can provide extended remission periods. Organizations like the American Cancer Society provide comprehensive information about transplant procedures. For those with relapsed myeloma, newer options include monoclonal antibodies and CAR-T cell therapy, which harness the immune system to target cancer cells.

Living With Myeloma: Prognosis and Support

While multiple myeloma remains incurable for most patients, survival rates have improved dramatically in the past two decades. Many patients now live for years or even decades with the disease through effective management strategies. The myeloma survival rate varies based on stage at diagnosis, genetic features of the disease, and response to treatment.

Support groups play a vital role in helping patients cope with the challenges of myeloma. The International Myeloma Foundation offers resources for patients and caregivers, including local support group connections. Managing bone health is particularly important, as bone complications are common in myeloma patients.

Clinical trials represent an important option for many patients, offering access to promising new treatments before they become widely available. The National Cancer Institute maintains a database of active clinical trials for myeloma patients. Working closely with a myeloma specialist, preferably at a center with expertise in blood cancers, can help patients make informed decisions about their care journey.

Conclusion

Multiple myeloma presents complex challenges, but advances in treatment have transformed it from a rapidly fatal disease to a manageable chronic condition for many patients. Early diagnosis, comprehensive care from specialists, and ongoing research continue to improve outcomes. If you or someone you love is facing a myeloma diagnosis, connecting with specialized healthcare providers and support organizations can make a significant difference in the journey ahead. With continued research and emerging therapies, there is growing hope for myeloma patients, with each year bringing new treatment options and improved quality of life.

Citations

This content was written by AI and reviewed by a human for quality and compliance.